AARP Eye Center
In 1959, doctors in Philadelphia reported actual reproductive malformation in a DES (Diethystilbestrol) Daughter. Albert M. Bongiovanni, et al., "Masculinization of the female infant associated with estrogenic therapy alone during gestation:
Four Cases per the Journal of Clinical Endocrinology and Metabolics 1004 (1959)....yet the Tragedy continued.
The producers of DES (Diethystilbestrol) made no effort to alert the government or the medical community of the drug's dangers!
In a DES Breast Cancer case conducted it Boston it was said that “During the period defendants marketed DES, they knew or should have known it was a carcinogenic substance, that there was a grave danger after varying periods of latency it would cause cancerous and precancerous growths in the daughters of the mothers who took it, and that it was ineffective to prevent miscarriage.
Nevertheless, defendants continued to advertise and market the drug as a miscarriage preventative.
They failed to test DES for efficacy and safety; the tests performed by others, upon which they relied, indicated that it was not safe of effective.
In violation of the authorization of the FDA, defendants marketed DES on an unlimited basis rather than as an experimental drug, and they failed to warn of its potential danger” The DES exposed are still awaiting an apology for this tragedy!
#Diethylstilbestrol #TheDESTragedy
"I downloaded AARP Perks to assist in staying connected and never missing out on a discount!" -LeeshaD341679
